RxDoctor Payments Data

Jack Maxwell, DO

Family Medicine · Hickory Creek, TXNPI 1679585087

Payments from drug & device makers

$2,120in general payments, 2019–2025

Across 125 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$526
  • Amgen$402
  • GSK$367
  • Novo Nordisk$287
  • Jazz Pharmaceuticals Inc.$94
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • plus $388 from 16 others

What the payments were for

  • Food & beverage$2,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,120 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$100,557
Medicare patients
380
Services billed
1,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$74,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$39,508
FarxigaDapagliflozin Propanediol31$35,982
EliquisApixaban30$30,359
JardianceEmpagliflozin12$19,683
XareltoRivaroxaban12$18,048
Breo ElliptaFluticasone/Vilanterol27$11,860
Soliqua 100-33Insulin Glargine/Lixisenatide11$11,755
MyrbetriqMirabegron11$10,330
LinzessLinaclotide11$8,183
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,818
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,874
SymbicortBudesonide/Formoterol Fumarate17$3,746
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,531
Levothyroxine Sodium289$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$287$74,16254 claims
GSKTrelegy Ellipta, Breo Ellipta$367$51,36877 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$526$46,54659 claims
PfizerEliquis$15$30,35930 claims
Boehringer IngelheimJardiance$37$19,68312 claims
Johnson & JohnsonXarelto$20$18,04812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Hickory Creek

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →